Anterior Uveitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anterior Uveitis – Drugs In Development, 2024 report and make more profitable business decisions.
Inflammation of the eyes is known as Uveitis. If inflammation occurs at the anterior portion of the eye (iris) it is known as anterior uveitis. Uveitis damages the uvea, the middle layer of the eye consisting of the iris, ciliary body, and choroid. Common causes are any trauma to the eye, underlying health issues like diabetes, viral infections HSV, syphilis, TB, and other causes. Redness, itchiness, blurred vision, and sensitivity to light are common symptoms. This condition can be acute or chronic if left untreated or prevented. Glaucoma, cataract are complications associated with this. Anti-inflammatory drugs as eye drops, injections, are prescribed. Steroid induced glaucoma can result in uveitis hence not recommended in complicated cases.
The Anterior Uveitis drugs in development market research report provide comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anterior Uveitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anterior Uveitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anterior Uveitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anterior Uveitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
BioNanoSim LtdElasmogen Ltd
Eyevensys SAS
Louisiana State University Health Sciences Center New Orleans
Oculis Holding AG
Pharmapraxis
Sandoz Group AG
Tarsier Pharma Ltd
Viva Vision Biotech
Wuhan Healthgen Biotechnology Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anterior Uveitis reports